Nonnucleoside inhibitors of norovirus rna polymerase: Scaffolds for rational drug design

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3115-3123

  Eltahla, Auda A ^a   Lim, Kun Lee ^a,b   Eden, John Sebastian ^c   Kelly, Andrew G ^a   Mackenzie, Jason M ^d   White, Peter A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c University of Sydney   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2' METHYLCYTIDINE; ANTIVIRUS AGENT; NIC02; NIC04; NIC10; NIC12; RNA DIRECTED RNA POLYMERASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA; RECOMBINANT PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; ENZYME INHIBITION; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NOROVIRUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; ANTAGONISTS AND INHIBITORS; CALICIVIRIDAE INFECTIONS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GASTROENTERITIS; GENETICS; IC50; TUMOR CELL LINE; VIROLOGY;

ANTIVIRAL AGENTS; CALICIVIRIDAE INFECTIONS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; GASTROENTERITIS; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; NOROVIRUS; RECOMBINANT PROTEINS; REPLICON; RNA REPLICASE; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901268195     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02799-13     Document Type: Article

References (39)

1. Estes MK, Prasad BV, Atmar RL. 2006. Noroviruses everywhere: has something changed? Curr. Opin. Infect. Dis. 19:467-474. http://dx.doi.org/10. 1097/01.qco.0000244053.69253.3d.
2. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224-1231. http://dx.doi.org/10.3201/eid1408.071114.
3. Tu ET, Bull RA, Greening GE, Hewitt J, Lyon MJ, Marshall JA, McIver CJ, Rawlinson WD, White PA. 2008. Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b. Clin. Infect. Dis. 46:413-420. http://dx.doi.org/10.1086/525259.
4. Bok K, Green KY. 2012. Norovirus gastroenteritis in immunocompromised patients. N. Engl. J. Med. 367:2126-2132. http://dx.doi.org/10.1056/ NEJMra1207742.
5. Bull RA, Eden JS, Luciani F, McElroy K, Rawlinson WD, White PA. 2012. Contribution of intra- and interhost dynamics to norovirus evolution. J. Virol. 86:3219-3229. http://dx.doi.org/10.1128/JVI.06712-11.
6. Hoffmann S, Batz MB, Morris JG, Jr. 2012. Annual cost of illness and quality-Adjusted life year losses in the United States due to 14 foodborne pathogens. J. Food Prot. 75:1292-1302. http://dx.doi.org/10.4315/0362-028X.JFP- 11-417.
7. Tu ET, Bull RA, Kim MJ, McIver CJ, Heron L, Rawlinson WD, White PA. 2008. Norovirus excretion in an aged-care setting. J. Clin. Microbiol. 46:2119-2121. http://dx.doi.org/10.1128/JCM.02198-07.
8. Green KY, Chanock RM, Kapikan AZ. 2001. Human calicivirus, p 841-874. In Knipe DM, Howley PM (ed), Fields virology, 4th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
9. Jiang X, Wang M, Wang K, Estes MK. 1993. Sequence and genomic organization of Norwalk virus. Virology 195:51-61. http://dx.doi.org/10.1006/ viro.1993.1345.
10. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. 2004. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85:79-87. http://dx.doi.org/10.1099/vir.0.19478-0.
11. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW. 2003. STAT1- dependent innate immunity to a Norwalk-like virus. Science 299:1575-1578. http://dx.doi.org/10.1126/science.1077905.
12. Wobus CE, Karst SM, Thackray LB, Chang KO, Sosnovtsev SV, Belliot G, Krug A, Mackenzie JM, Green KY, Virgin HW. 2004. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2:e432. http://dx.doi.org/10.1371/journal.pbio.0020432.
13. Taube S, Kolawole AO, Hohne M, Wilkinson JE, Handley SA, Perry JW, Thackray LB, Akkina R, Wobus CE. 2013. A mouse model for human norovirus. MBio 4:e00450-13. http://dx.doi.org/10.1128/mBio.00450-13.
14. Chang K-O, Sosnovtsev SV, Belliot G, King AD, Green KY. 2006. Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353:463-473. http://dx.doi.org/10.1016/j.virol.2006.06.006.
15. Aghemo A, De Francesco R. 2013. New horizons in hepatitis C antiviral therapy with direct-Acting antivirals. Hepatology 58:428-438. http://dx.doi.org/10.1002/hep.26371.
16. Högbom M, Jäger K, Robel I, Unge T, Rohayem J. 2009. The active form of the norovirus RNA-dependent RNA polymerase is a homodimer with cooperative activity. J. Gen. Virol. 90:281-291. http://dx.doi.org/10.1099/vir. 0.005629-0.
17. Lee J-H, Alam I, Han KR, Cho S, Shin S, Kang S, Yang JM, Kim KH. 2011. Crystal structures of murine norovirus-1 RNA-dependent RNA polymerase. J. Gen. Virol. 92:1607-1616. http://dx.doi.org/10.1099/vir.0.031104-0.
18. Ng KK-S, Pendás-Franco N, Rojo J, Boga JA, Machín A, Alonso JMM, Parra F. 2004. Crystal structure of Norwalk virus polymerase reveals the carboxyl terminus in the active site cleft. J. Biol. Chem. 279:16638-16645. http://dx.doi.org/10.1074/jbc.M400584200.
19. Rohayem J, Bergmann M, Gebhardt J, Gould E, Tucker P, Mattevi A, Unge T, Hilgenfeld R, Neyts J. 2010. Antiviral strategies to control calicivirus infections. Antiviral Res. 87:162-178. http://dx.doi.org/10.1016/j.antiviral. 2010.05.002.
20. Kim Y, Lovell S, Tiew K-C, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang K-O. 2012. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 86:11754-11762. http://dx.doi.org/10.1128/JVI.01348-12.
21. Tiew K-C, He G, Aravapalli S, Mandadapu SR, Gunnam MR, Alliston KR, Lushington GH, Kim Y, Chang K-O, Groutas WC. 2011. Design, synthesis, and evaluation of inhibitors of Norwalk virus 3C protease. Bioorg. Med. Chem. Lett. 21:5315-5319. http://dx.doi.org/10.1016/j.bmcl.2011.07.016.
22. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MSJ, Neyts J. 2012. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res. Commun. 424:777-780. http://dx.doi.org/10.1016/j.bbrc. 2012.07.034.
23. Costantini VP, Whitaker T, Barclay L, Lee D, McBrayer TR, Schinazi RF, Vinje J. 2012. Antiviral activity of nucleoside analogues against norovirus. Antivir. Ther. 17:981-991. http://dx.doi.org/10.3851/IMP2229.
24. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Cunha R, Costa I, Nascimento MSJ, Neyts J. 2012. Inhibition of norovirus replication by the nucleoside analogue 2-C-methylcytidine. Biochem. Biophys. Res. Commun. 427:796-800. http://dx.doi.org/10.1016/j.bbrc.2012.10.003.
25. Mastrangelo E, Pezzullo M, Tarantino D, Petazzi R, Germani F, Kramer D, Robel I, Rohayem J, Bolognesi M, Milani M. 2012. Structure-based inhibition of Norovirus RNA-dependent RNA polymerases. J. Mol. Biol. 419:198-210. http://dx.doi.org/10.1016/j.jmb.2012.03.008.
26. Bull RA, Hyde J, Mackenzie JM, Hansman GS, Oka T, Takeda N, White PA. 2011. Comparison of the replication properties of murine and human calicivirus RNA-dependent RNA polymerases. Virus Genes 42:16-27. http://dx.doi.org/10.1007/ s11262-010-0535-y.
27. Jones LA, Clancy LE, Rawlinson WD, White PA. 2006. High-Affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity. Antimicrob. Agents Chemother. 50:3019-3027. http://dx.doi.org/10.1128/AAC.01603- 05.
28. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
29. Eltahla AA, Lackovic K, Marquis C, Eden JS, White PA. 2013. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virusRNApolymerase. J. Biomol. Screen. 18:1027-1034. http://dx.doi.org/10.1177/1087057113489883.
30. Eden JS, Bull RA, Tu E, McIver CJ, Lyon MJ, Marshall JA, Smith DW, Musto J, Rawlinson WD, White PA. 2010. Norovirus GII.4 variant 2006b caused epidemics of acute gastroenteritis in Australia during 2007 and 2008. J. Clin. Virol. 49:265-271. http://dx.doi.org/10.1016/j.jcv.2010.09.001.
31. McCartney SA, Thackray LB, Gitlin L, Gilfillan S, Virgin HW, Colonna M. 2008. MDA-5 recognition of a murine norovirus. PLoS Pathog. 4:e1000108. http://dx.doi.org/10.1371/journal.ppat.1000108.
32. Rocha-Pereira J, Jochmans D, Debing Y, Verbeken E, Nascimento MS, Neyts J. 2013. The viral polymerase inhibitor 2-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J. Virol. 87:11798-11805. http://dx.doi.org/10.1128/JVI.02064- 13.
33. Rocha-Pereira J, Cunha R, Pinto DC, Silva AM, Nascimento MS. 2010. (E)-2-styrylchromones as potential anti-norovirus agents. Bioorg. Med. Chem. 18:4195-4201. http://dx.doi.org/10.1016/j.bmc.2010.05.006.
34. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9:671-675. http://dx.doi.org/10.1038/ nmeth.2089.
35. Sykes ML, Baell JB, Kaiser M, Chatelain E, Moawad SR, Ganame D, Ioset J-R, Avery VM. 2012. Identification of compounds with antiproliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl. Trop. Dis. 6:e1896. http://dx.doi.org/10.1371/journal. pntd.0001896.
36. Zhang JH, Chung TDY, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73. http://dx.doi.org/10.1177/1087057199 00400206.
37. Campagnola G, Gong P, Peersen OB. 2011. High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. Antiviral Res. 91:241-251. http://dx.doi.org/10.1016/j.antiviral.2011.06.006.
38. Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53:2719-2740. http://dx.doi.org/10.1021/ jm901137j.
39. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46:977-981. http://dx.doi.org/10.1128/AAC.46.4.977-981.2002.